<?xml version="1.0" encoding="UTF-8"?>
<p>As noted, we recently evaluated the effectiveness of MTX in pain reduction using a visual analog scale (VAS) (0â€“10) with higher values indicating more severe pain [
 <xref rid="B41-viruses-11-00289" ref-type="bibr">41</xref>]. We treated 48 Brazilian CCA patients who were seen 14.2 (SD, 4.2) months after the onset of disease. Sixty percent of the patients had arthralgia. Forty percent also had arthritis. The patients received MTX 7.5 mg/week with folic acid, with dose escalations for refractory symptoms at 4 weeks. The final mean MTX dose was 9.2 (SD, 3.2) mg/week. The mean reductions in pain at 4 and 8 weeks, compared to baseline, were 4.3 (3.0) (
 <italic>p</italic> &lt; 0.0001) and 4.5 (2.6) (
 <italic>p</italic> &lt; 0.0001), respectively [
 <xref rid="B41-viruses-11-00289" ref-type="bibr">41</xref>]
</p>
